Src tyrosine kinase inhibition restores sensitivity to paclitaxel-resistant ovarian cancer cells. Pharmacologic inhibition of Src tyrosine kinase was shown to resensitize paclitaxel-resistant mouse and human ovarian cancer cells. To demonstrate specificity, mouse ID8 paclitaxel-resistant ovarian cancer cells were transfected with a Src dominant-negative-EGFP fusion construct (right panels) or EGFP as control (left panels). Cells were then exposed to paclitaxel for 24 hours. Note the fragmented nucleus, indicative of apoptosis, in the Src dominant-negative expressing cell. For details, see Chen et al. in this issue (pp. 217–224).